TABLE 3.
N | Model 1 c HR (95%CI) | p‐value | N | Model 2 d HR (95%CI) | p‐value | |
---|---|---|---|---|---|---|
Continuous concentration | 316 | 1.003 (1.00–1.01) | .004* | |||
Concentration divided on median a | 316 | 1.550* (1.11–2.16) | .01* | |||
Concentrations divided in four quartiles b | ||||||
Lowest quartile | 316 | Ref. | 243 | Ref. | ||
Second quartile | 0.767 (0.47–1.27) | .300 | 0.645 (0.37–1.13) | .127 | ||
Third quartile | 1.271 (0.81–2.00) | .299 | 1.099 (0.66–1.84) | .720 | ||
Highest quartile | 1.470 (0.93–2.32) | .097 | 1.073 (0.63–1.84) | .798 |
Note: Data presented as hazard ratio with a 95% confidence interval. Number of events model 1: n = 154. Number of events model 2: n = 118.
Abbreviations: N, number of analyzed plasma concentrations; CI, confidence interval.
Median concentration selective beta‐blocker: 16.95 ng/mL.
Concentration selective beta‐blocker 25th percentile: 8.61 ng/mL; 75th percentile: 46.5 ng/mL.
Model 1 was adjusted for age and gender.
Model 2 was adjusted for age, gender, eGFR, and CV disease. No model 2 was constructed for the continuous and binary metoprolol concentration because none of the added variables changed the outcome more than 10%.
p‐value ≤.05.